B. Metzler Seel. Sohn & Co. Ag Zai Lab LTD Transaction History

B. Metzler Seel. Sohn & Co. Ag

6 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q4 2023 Feb 13, 2024	BUY	$22.97 - $30.58 $211,369 - $281,397	9,202 New	9,202 $251,000
Q2 2023 Aug 11, 2023	BUY	$25.3 - $39.67 $30,360 - $47,604	1,200 Added 17.64%	8,002 $221,000
Q1 2023 May 10, 2023	BUY	$30.21 - $48.1 $205,488 - $327,176	6,802 New	6,802 $226,000
Q2 2022 Aug 12, 2022	SELL	$23.14 - $49.68 $131,944 - $283,275	-5,702 Closed	0 $0
Q1 2022 May 10, 2022	SELL	$27.77 - $64.4 $27,770 - $64,400	-1,000 Reduced 14.92%	5,702 $251,000
Q4 2021 Feb 11, 2022	BUY	$54.9 - $105.21 $367,939 - $705,117	6,702 New	6,702 $448,000

116

40.8M

63.1K

420K

Ticker ZLAB
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 97,908,704
Market Cap $3.02B
Description
Zai Lab Limited develops and commercializes therapies to treat oncology, autoimmune disorders, infectious diseases, and neuroscience primarily in Mainland China and Hong Kong. The company's commercial products include Zejula, a once-daily small-molecule poly polymerase 1/2 inhibitor; Optune, a device that delivers tumor treating fields; NUZYRA f...

Get notified when there are updates to the investment portfolio of B. Metzler Seel. Sohn & Co. Ag, based on Form 13F filings with the SEC.

Stay updated on B. Metzler Seel. Sohn & Co. Ag with notifications on news.